Repair
11Tendon, ligament, muscle, joint/cartilage and exercise-recovery claims.
Injury recoveryBlend
Wolverine Stack
BPC-157 plus TB-500, with untested combination effects
Community reportsInjury recovery3
Investigational; this profile does not establish an approved use.
What does it do?
A community BPC-157/TB-500 repair combination without a controlled human trial establishing benefit or safety.
Approved & studied uses
No established medical use is documented for this formulation.
Evidence limits
View research →Component studies do not establish combination efficacy or safety.3
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Combination uncertainty
Component studies do not establish combination efficacy or safety.3
Investigational; this profile does not establish an approved use.
Molecular information
Amino-acid sequence
This blend contains multiple compounds and has no single amino-acid sequence.
Multiple componentsComposition varies
LengthMultiple components
Molecular weight · DaMixture; requires component identity and amounts
Formula, sequence notation & identity
Molecular formulaMixture; no single formula3
Community combination; exact component identity and ratio depend on product
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pharmacokinetics
How long does it stay in the body?
Reported half-lifeHuman kinetics not established3
This multi-component blend has no single half-life. Animal BPC-157 kinetics and full-length thymosin beta-4 data cannot define its human clearance.
What to expect
Study outcomes
Reported timelines
Reference & communitySource expectations
Pain/inflammation 1–2 weeks, recovery 2–4, chronic injuries 4–6, structural change 6–8; oral GI 1–4+. Unvalidated forecasts.11
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 9 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1306 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
87.5% figure comes from a small uncontrolled knee review, not a Wolverine Stack efficacy trial.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 250 mcg BPC-157 + 250 mcg TB-500Starting dose | Once daily | Conservative startReference report | 4-8 weeks | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. 87.5% figure comes from a small uncontrolled knee review, not a Wolverine Stack efficacy trial. Source tabs Injectable | |||||
| SubQ | 500 mcg BPC-157 + 500 mcg TB-500 | Once daily | General Recovery ProtocolReference report | 4-8 weeks | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. 87.5% figure comes from a small uncontrolled knee review, not a Wolverine Stack efficacy trial. Source tabs Injectable | |||||
| SubQ | BPC-157 250-500 mcg + TB-500 2 mg | BPC-157 once daily, TB-500 twice weekly | General Recovery Protocol (separate vials)Reference report | 4-8 weeks | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. 87.5% figure comes from a small uncontrolled knee review, not a Wolverine Stack efficacy trial. Source tabs Injectable | |||||
| SubQSubQ near injury site | BPC-157 500 mcg + TB-500 2.5 mg | BPC-157 1-2x daily, TB-500 twice weekly | Intensive Injury Recovery (separate vials)Reference report | 4-8 weeks | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. 87.5% figure comes from a small uncontrolled knee review, not a Wolverine Stack efficacy trial. Source tabs Injectable | |||||
| OralOral capsule or sublingual | BPC-157: 500 mcg-1 mg | Once daily on empty stomach | GI Support ProtocolReference report | 4-8 weeks | 11 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. 87.5% figure comes from a small uncontrolled knee review, not a Wolverine Stack efficacy trial. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 4-8 weeks
- Break
- 4 weeks between cycles
Reported timing
Consistent daily time preferred. Morning is most common in community practice. No fasting required.
Oral
- Use period
- 4-8 weeks
- Break
- 4 weeks between cycles
Reported timing
Morning on empty stomach
Side effects & safety
Combination uncertainty
Component studies do not establish combination efficacy or safety.
3Identity uncertainty
Some references concern full-length thymosin beta-4 rather than the TB-500 fragment.
3Reported combination reaction
A spontaneous report describes recurring skin and gingival darkening after a combination product; it cannot establish incidence or identify which ingredient caused it.
2Unknown safety
Cancer/angiogenesis concerns, pregnancy/breastfeeding uncertainty and untested blend interactions.
Stop symptoms
Abnormal lumps/growth, infected/severely inflamed sites, allergy, unexpected bleeding/bruising, persistent headache/vision changes or GI symptoms.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
NSAIDs
Caution reportedGI protection not established in people.11
Reference report · Pep-Pedia label: Monitor CombinationCorticosteroids
Caution reportedPotential healing antagonism.11
Reference report · Pep-Pedia label: Use CautionAnticoagulants
Caution reportedBleeding concern unquantified.11
Reference report · Pep-Pedia label: Monitor CombinationChemotherapy
Avoidance reportedTheoretical angiogenesis concern.11
Reference report · Pep-Pedia label: Avoid CombinationHGH
Unverified pairingUnproven repair stack.11
Reference report · Evidence context: SynergisticCJC-1295 / Ipamorelin
Unverified pairingUntested pairing.11
Reference report · Pep-Pedia label: SynergisticPEG-MGF
Unverified pairingUntested growth/repair pairing.11
Reference report · Pep-Pedia label: SynergisticGHK-Cu
Unverified pairingUntested pairing.11
Reference report · Pep-Pedia label: CompatibleOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.3
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source distinguishes an equal-part blend from separate BPC-157 and TB-500 vials.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Equal-part 10 mg blend in 2 mL: 0.1 mL contains 250 mcg of each peptide. · Reported storage: 2–8°C for 30 days. · Separate-vial handling must retain each component’s own concentration and schedule.
The concentration example assumes exactly 5 mg of each component; other blend ratios give different component amounts.
Oral
The source describes oral BPC-157 while explicitly noting that oral TB-500 use is not well established.
- Form
- Source describes a prepared product
- Reported parameters
- Its oral timing report is 30 minutes before food.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite Lyophilized PowderReported appearanceClear After ReconstitutionReported variationMinor Clumping AcceptableReported concernCollapsed or DiscoloredReported concernCloudy or ParticlesReported appearanceCertificate of Analysis
11Available forms
No verified packaging examples included.
Amounts are total blend mass. Formulas and ratios vary. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
11Lyophilized vial at room temperature before reconstitution. After reconstitution, refrigerate at 2-8°C and use within 30 days.
Per product instructions
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
No blend trialsSource context
87.5% figure comes from a small uncontrolled knee review, not a Wolverine Stack efficacy trial.
Compound identity & other names
Wolverine Stack is a community name for combining BPC-157 and TB-500. A fixed mixture, separate vials and full-length thymosin beta-4 are different interventions; no direct controlled blend trial was verified.
Other names: Wolverine · BPC-157 + TB-500
Investigational; this profile does not establish an approved use.
How it may work
Proposed complementary repair signaling is largely extrapolated from separate compounds and full-length Tβ4.11
No direct blend trial verified
Pep-Pedia cites component research and reviews, which do not establish additive benefit or a validated blend schedule.
3Source checks & newer research
Retrospective knee-pain BPC-157 report
16 respondents: 12 received BPC-157 alone (11 improved); four received BPC-157 plus TB4 (three improved). No control group or validated functional measures; 87.5% overall is not evidence of stack synergy or TB-500-fragment efficacy.
Uncontrolled retrospective series12Research areas and evidence gaps
- Component studies do not establish combination efficacy or safety.
- Some references concern full-length thymosin beta-4 rather than the TB-500 fragment.
- There is no universal blend ratio or single molecular weight.
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.3
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
No direct controlled trial of this named blend was identified in the targeted check. Component literature is retained separately from blend claims.
- Checked
- 2026-10-12
- Search
- Wolverine BPC-157 TB-500 clinical trial
- Catalog
- Pep-Pedia ↗ · 8 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainComponent research or community information does not establish effects of this blend.Abstract checked
AI-PREPARED SUMMARY
Retrospective telephone follow-up: 11 of 12 BPC-only recipients reported pain improvement. No comparator or objective healing endpoint; a hypothesis-generating case series.
Pep-Pedia bibliography · Checked 2026-10-12
2FDA assessment: reported BPC-157/TB-500 product reactionComponent research or community information does not establish effects of this blend.Primary source checked
AI-PREPARED SUMMARY
A reported pigmentation reaction recurred after rechallenge with a combination product. The assessment could not isolate the responsible component.
Additional research · Checked 2026-10-12
3Pep-Pedia: Wolverine StackComponent research or community information does not establish effects of this blend.Community source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
No direct blend trial verified
Pep-Pedia cites component research and reviews, which do not establish additive benefit or a validated blend schedule.
4Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal.Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The orthopedic review mainly describes preclinical BPC-157 repair findings; it does not establish the combined Wolverine product's efficacy.
Reported population / model
Systematic Review
Reported study details
36 articles · Orthopedic sports medicine focus
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Treadwell T, Kleinman HK, Crockford D, et al. (2012). The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences.Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Some topical thymosin-beta-4 trial responders healed ulcers sooner; responder-specific findings cannot establish a systemic blend effect.
Reported population / model
Human Phase 2
Reported study details
Stasis and pressure ulcers · Accelerated healing
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37-51.Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review surveys full thymosin-beta-4 regeneration mechanisms; commercial TB-500 identity and a two-component stack remain separate questions.
Reported population / model
Review
Reported study details
Multi-functional peptide · Clinical applications
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7BPC-157 Achilles Tendon Healing (2003)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat BPC-157 tendon experiments reported better mechanics and function; the combined stack was not tested.
Reported population / model
Rats
Reported study details
10 μg/kg i.p. daily · 14 days · Improved biomechanics
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Thymosin β4 Wound Healing Acceleration (1999)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat wound experiments reported faster surface repair, collagen and vessel formation with thymosin beta-4 alone; this does not validate the blend.
Reported population / model
Rats
Reported study details
Full thickness wounds · 42-61% faster re-epithelialization
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Treadwell T, Kleinman HK, Crockford D, et al. (2012). The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences.Component research or community information does not establish effects of this blend.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
10Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37-51.Component research or community information does not establish effects of this blend.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Pep-Pedia: Wolverine Stack — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
12Retrospective knee-pain BPC-157 reportPrimary source checked
AI-PREPARED SUMMARY
16 respondents: 12 received BPC-157 alone (11 improved); four received BPC-157 plus TB4 (three improved). No control group or validated functional measures; 87.5% overall is not evidence of stack synergy or TB-500-fragment efficacy.
Retrospective knee-pain BPC-157 report
16 respondents: 12 received BPC-157 alone (11 improved); four received BPC-157 plus TB4 (three improved). No control group or validated functional measures; 87.5% overall is not evidence of stack synergy or TB-500-fragment efficacy.
Additional primary-source check · Checked 2026-10-12